Effects of salvianolate on microcirculatory disturbance in patients with stable coronary heart disease: study protocol for a randomized controlled trial

• Published in: Current controlled trials in cardiovascular medicine 2021-03, Vol.22 (1), p.192-192, Article 192
• Main Authors: Li, Zhanlu, Luan, Yi, Wang, Min, Li, Ya, Shen, Xiaohua, Fu, Guosheng, Zhang, Wenbin
• Format: Article
• Language: English
• Subjects: Angina pectoris; Blood tests; Cardiovascular disease; Care and treatment; Coronary heart disease; Coronary microcirculation; Coronary vessels; Creatinine; Diagnosis; Electrocardiography; Enrollments; Informed consent; Ischemia; Medical imaging; Patients; Potassium; Quality of life; Salvianolate; Study Protocol; Uric acid; Veins & arteries
• ISSN: 1745-6215; 1745-6215
• DOI: 10.1186/s13063-021-05099-7

Obstruction of coronary microcirculation can lead to myocardial ischemia and poor prognosis. Salvianolate exerts cardiovascular protection at cellular levels. However, no studies have confirmed the effect of salvianolate on stable coronary heart disease (CHD) with high fractional flow reserve (FFR) and myocardial microcirculatory disturbances. This study will enroll 78 patients who have stable coronary disease with 50 to 70% stenosis in major coronary arteries and whose FFR > 0.80 and index of microcirculatory resistance (IMR) > 25. Patients will be randomly divided into the salvianolate group or the placebo group. After above evaluations, salvianolate 200 mg will be intravenously dripped immediately for the next 30 min and subsequent 7 days in the salvianolate group, and matching 0.9% normal saline will be arranged in the placebo group. IMR will be reevaluated in immediate phase after first 30 min of salvianolate or placebo treatment. The primary end point will be the IMR change in this phase, and the secondary end points will be the total ischemic burden assessed by the Seattle angina scale, quality of life scale, Holter electrocardiography, and 6-min walk test after 7 days before discharge. This study will firstly clarify the improvement effect of salvianolate on coronary microcirculation and provide an effective treatment method for stable CHD patients with high FFR and myocardial microcirculatory disturbance. Chinese Clinical Trial Registry ChiCTR1800018772 . Registered on 9 October 2018 and updated on 2 March 2020.